| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer | Phase 1/2 | BioNTech SE | Basking Ridge |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement | Phase 4 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Blood Pressure Control During Cancer Treatment | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC) | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Language Interpretation Solutions for People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Revaree Plus in People With Breast Cancer | Phase 4 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Romosozumab in People With Breast Cancer and Osteoporosis | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Skipping Radiation Therapy in People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of Surgery and Radiotherapy in People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a Decision Tool for People Considering Breast Reconstruction Surgery | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of a Side Effects and Resource Navigation Program for People With Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer | Phase 1 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | Basking Ridge |
| Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Factors Associated With Breast Cancer Risks and Outcomes | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol | Phase 4 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Lymphedema Surveillance Study | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Researching the Effect of Exercise on Cancer | N/A | City of Hope Medical Center | Basking Ridge |
| Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations | — | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Study of Aerobic Training for People Receiving Treatment for Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job | N/A | Memorial Sloan Kettering Cancer Center | Basking Ridge |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | Phase 3 | NRG Oncology | Basking Ridge |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | Belleville |
| DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment | Phase 4 | Rutgers, The State University of New Jersey | Belleville |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | LeonaBio | Belleville |
| RADIANT: Pre-op Radiation With Abemaciclib and Letrozole | Phase 1 | Mridula George, MD | Belleville |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | Berkeley Heights |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy | Phase 3 | Hoffmann-La Roche | Camden |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | Camden |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | Camden |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | Camden |
| Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes | — | The Cooper Health System | Camden |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | Camden |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | Camden |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | Camden |
| Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | Camden |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | Camden |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | N/A | Natera, Inc. | Camden |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | Cape May Court House |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | Cherry Hill |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | Cherry Hill |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | Phase 3 | National Cancer Institute (NCI) | Cherry Hill |
| Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery | N/A | Thomas Jefferson University | Cherry Hill |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | East Brunswick |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | Pliant Therapeutics, Inc. | East Brunswick |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | East Brunswick |
| A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) | Phase 3 | Genentech, Inc. | East Brunswick |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | East Brunswick |
| A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Phase 1 | Cogent Biosciences, Inc. | East Brunswick |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | East Brunswick |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease | Phase 3 | BeOne Medicines | East Brunswick |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | East Brunswick |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | East Brunswick |
| Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | East Brunswick |
| RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive | Phase 2/3 | Hoffmann-La Roche | East Brunswick |
| SLV-154 Treatment of Advanced Cancers | Phase 1 | Solve Therapeutics | East Brunswick |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | East Brunswick |
| To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer | Phase 2 | Hoffmann-La Roche | East Brunswick |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | Elizabeth |
| Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer | Phase 2 | Rutgers, The State University of New Jersey | Elizabeth |
| Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | Phase 2 | Rutgers, The State University of New Jersey | Elizabeth |
| Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Phase 2 | Rutgers, The State University of New Jersey | Elizabeth |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | Englewood |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | Englewood |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | Englewood |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Phase 3 | American Society of Clinical Oncology | Englewood |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | Flemington |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | Flemington |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | Florham Park |
| Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | N/A | Novian Health Inc. | Florham Park |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | — | Tempus AI | Florham Park |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | Florham Park |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | Phase 1/2 | Hoffmann-La Roche | Freehold |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase 1 | LigaChem Biosciences, Inc. | Hackensack |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Phase 1 | Normunity AccelCo, Inc. | Hackensack |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | Hackensack |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | Hackensack |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | Hackensack |
| A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | Hackensack |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | Hackensack |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | Hackensack |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | Hackensack |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | Hackensack |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | Hackensack |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | Hackensack |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | Hackensack |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | Hackensack |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | Hackensack |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | Hackensack |
| Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | Phase 1/2 | Vironexis Biotherapeutics Inc. | Hackensack |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | Hackensack |
| RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer | Phase 1/2 | Georgetown University | Hackensack |
| A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery | Phase 1/2 | Memorial Sloan Kettering Cancer Center | Montvale |
| A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Phase 2 | GlaxoSmithKline | Morristown |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | Morristown |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Exelixis | New Brunswick |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | New Brunswick |
| A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | New Brunswick |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | New Brunswick |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | New Brunswick |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | New Brunswick |
| Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer | N/A | Rutgers, The State University of New Jersey | New Brunswick |
| KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | Phase 1 | Christian Hinrichs | New Brunswick |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | Phase 2 | Oana Danciu | New Brunswick |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | New Brunswick |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | Phase 1/2 | Merck Sharp & Dohme LLC | New Brunswick |
| SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers | N/A | Beth Israel Deaconess Medical Center | Newark |
| Rutgers University Study of the Genetics of Breast Cancer. | — | Rutgers, The State University of New Jersey | Piscataway |
| A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials | N/A | Abramson Cancer Center at Penn Medicine | Plainsboro |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | Plainsboro |
| Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | Phase 1 | Cellectar Biosciences, Inc. | Princeton |
| Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | Phase 1 | Novartis Pharmaceuticals | Princeton |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | Sewell |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | Summit |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | Phase 3 | Daiichi Sankyo | Summit |
| Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs | — | SpotitEarly | Totowa |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | N/A | M.D. Anderson Cancer Center | Voorhees Township |
| Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | Voorhees Township |